BRPI0517640A - composições farmacêuticas tópicas contendo um composto antiacne e um composto antibiótico - Google Patents

composições farmacêuticas tópicas contendo um composto antiacne e um composto antibiótico

Info

Publication number
BRPI0517640A
BRPI0517640A BRPI0517640-9A BRPI0517640A BRPI0517640A BR PI0517640 A BRPI0517640 A BR PI0517640A BR PI0517640 A BRPI0517640 A BR PI0517640A BR PI0517640 A BRPI0517640 A BR PI0517640A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical compositions
compositions containing
antibiotic
topical pharmaceutical
Prior art date
Application number
BRPI0517640-9A
Other languages
English (en)
Inventor
G N Chaudhari
V S Khachane
N B Bhamre
Jagannath Macharla
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of BRPI0517640A publication Critical patent/BRPI0517640A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

COMPOSIçõES FARMACEUTICAS TóPICAS CONTENDO UM COMPOSTO ANTIACNE E UM COMPOSTO ANTIBIóTICO. Composições farmacêuticas adequadas para o tratamento de distúrbio da pele são fornecidas as quais incluem pelo menos uma quantidade terapeuticamente efetiva de pelo menos um agente antiacne e pelo menos um agente antibiótico como ingredientes farmacêuticos ativos e uma matriz hidrofilica capaz de fornecer uma liberação constante e uniforme dos ingredientes farmacêuticos ativos.
BRPI0517640-9A 2004-11-08 2005-11-08 composições farmacêuticas tópicas contendo um composto antiacne e um composto antibiótico BRPI0517640A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62587204P 2004-11-08 2004-11-08
PCT/IB2005/003302 WO2006048747A1 (en) 2004-11-08 2005-11-08 Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound

Publications (1)

Publication Number Publication Date
BRPI0517640A true BRPI0517640A (pt) 2008-10-14

Family

ID=36032111

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517640-9A BRPI0517640A (pt) 2004-11-08 2005-11-08 composições farmacêuticas tópicas contendo um composto antiacne e um composto antibiótico

Country Status (11)

Country Link
US (1) US20080075776A1 (pt)
EP (1) EP1841416A1 (pt)
KR (1) KR20070091613A (pt)
AU (1) AU2005300313B2 (pt)
BR (1) BRPI0517640A (pt)
CA (1) CA2586821A1 (pt)
MX (1) MX2007005444A (pt)
NZ (1) NZ555336A (pt)
RU (1) RU2404759C2 (pt)
WO (1) WO2006048747A1 (pt)
ZA (1) ZA200704467B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06008988A (es) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
EP2175935B1 (en) 2007-07-06 2018-10-24 Galderma Research & Development Topical composition containing adapalene for the treatment of keratinization disorders
EP2065032A1 (en) * 2007-11-27 2009-06-03 Galderma Research & Development A method for producing adapalene gels
CN101485675B (zh) * 2008-01-18 2012-05-02 兆科药业（合肥）有限公司 阿达帕林盐酸克林霉素复方凝胶制剂及其制备方法
WO2009116086A2 (en) 2008-03-17 2009-09-24 Glenmark Pharmaceuticals Limited Stable fixed dose topical formulation
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
CA2769640A1 (en) * 2009-07-30 2011-02-03 Allergan, Inc. Combination of dapsone with adapalene
ES2703253T3 (es) 2010-03-30 2019-03-07 Helperby Therapeutics Ltd Nueva combinación y uso
WO2012017215A1 (en) 2010-08-05 2012-02-09 Helperby Therapeutics Limited Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine
GB201013207D0 (en) 2010-08-05 2010-09-22 Helperby Therapeutics Ltd Novel combination
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
US20130245060A1 (en) 2010-10-08 2013-09-19 Helperby Therapeutics Limited Novel composition
US20140065209A1 (en) 2011-05-03 2014-03-06 Dupont Nutrition Biosciences Aps Probiotic bacteria for the topical treatment of skin disorders
GB201107755D0 (en) 2011-05-10 2011-06-22 Helperby Therapeutics Ltd Novel compounds
RU2498806C2 (ru) * 2011-12-09 2013-11-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав для лечения инфекционных воспалительных заболеваний в гинекологии и способ его получения
FR2991175B1 (fr) * 2012-06-01 2014-12-19 Galderma Res & Dev Compositions pharmaceutiques topiques de type emulsion h/e contenant un retinoide
RU2538680C2 (ru) * 2013-03-12 2015-01-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения атопического дерматита и способ ее получения
GB201305277D0 (en) 2013-03-22 2013-05-01 Helperby Therapeutics Ltd Novel combination and use
GB201307989D0 (en) 2013-05-02 2013-06-12 Helperby Therapeutics Ltd Novel combinations and use
GB201401617D0 (en) 2014-01-30 2014-03-19 Helperby Therapeutics Ltd Novel combination and use
CN107530397A (zh) 2014-12-18 2018-01-02 赫尔普百治疗有限公司 新型组合和用途
GB201518969D0 (en) 2015-10-27 2015-12-09 Helperby Therapeutics Ltd Triple combination
GB201620095D0 (en) 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
CN109310626A (zh) 2016-04-19 2019-02-05 美利坚合众国,由健康及人类服务部部长代表 革兰氏阴性种治疗特应性皮炎的用途
GB201610869D0 (en) 2016-06-22 2016-08-03 Helperby Therapeutics Ltd Combination
KR102093209B1 (ko) 2017-05-11 2020-03-25 (주)케어젠 이소트레티노인과 펩타이드의 결합체
GB201709193D0 (en) 2017-06-09 2017-07-26 Helperby Therapeutics Ltd Combination
CN107233565B (zh) * 2017-08-06 2021-08-20 殷晓英 一种复方护臀膏制备方法
CN108066332A (zh) * 2017-12-21 2018-05-25 兆科药业（广州）有限公司 一种凝胶制剂中阿达帕林的分散工艺
WO2019141957A1 (en) 2018-01-19 2019-07-25 Cado Biotechnology Ivs N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
KR20210013080A (ko) 2018-05-11 2021-02-03 포르테 서브시디어리, 인크. 피부 병태의 치료를 위한 조성물
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
BR112023020137A2 (pt) 2021-03-30 2023-11-28 Dupont Nutrition Biosci Aps Composições, comprimido, estojo e método para tratar e/ou prevenir a inflamação gastrointestinal
WO2025080755A1 (en) 2023-10-13 2025-04-17 Nutrition & Biosciences USA 4, Inc. Methods and compositions for aging and mitochondrial health

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497794A (en) * 1980-12-08 1985-02-05 Dermik Laboratories, Inc. Erythromycin/benzoyl peroxide composition for the treatment of acne
US5409917A (en) * 1991-03-05 1995-04-25 Marvin S. Towsend Topical treatment of acne with cephalosporins
DK1532974T3 (da) * 2002-03-12 2009-05-11 Galderma Res & Dev Sammensætning, der omfatter 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthsyre, til behandling af dermatologiske lidelser
US20030215493A1 (en) * 2002-04-30 2003-11-20 Patel Pravin M. Composition and method for dermatological treatment
RU2229872C1 (ru) * 2002-12-09 2004-06-10 Чухаджян Гарник Алексанович Средство местного действия, оказывающее стимулирующее влияние на процессы восстановления клеток
US7452547B2 (en) * 2004-03-31 2008-11-18 Johnson&Johnson Consumer Co., Inc. Product for treating the skin comprising a polyamine microcapsule wall and a skin lightening agent

Also Published As

Publication number Publication date
AU2005300313A1 (en) 2006-05-11
CA2586821A1 (en) 2006-05-11
EP1841416A1 (en) 2007-10-10
US20080075776A1 (en) 2008-03-27
MX2007005444A (es) 2007-08-23
RU2007121474A (ru) 2008-12-20
WO2006048747A1 (en) 2006-05-11
KR20070091613A (ko) 2007-09-11
WO2006048747A8 (en) 2006-08-31
RU2404759C2 (ru) 2010-11-27
ZA200704467B (en) 2008-07-30
AU2005300313B2 (en) 2011-05-26
NZ555336A (en) 2009-12-24

Similar Documents

Publication Publication Date Title
BRPI0517640A (pt) composições farmacêuticas tópicas contendo um composto antiacne e um composto antibiótico
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
ZA200803350B (en) Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
BRPI0813450B8 (pt) composto, formulação farmacêutica, e, usos do composto
PA8580201A1 (es) Terapia de combinacion para enfermedades hiperproliferativas
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
BRPI0318278B8 (pt) Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro
WO2010047765A8 (en) Nanostructures for drug delivery
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
UY28271A1 (es) Compuestos químicos
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
UY28366A1 (es) Compuestos químicos
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
CL2008000495A1 (es) Compuestos derivados de tetrahidro-pirazolo[4,3-c]piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alergias, inflamacion, dolor, cancer, entreotras.
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
CY1109507T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ελαστομερες οργανοπολυσιλοξανιο και μια διαλυτοποιημενη δραστικη ουσια
BRPI0511398A (pt) composição farmacêutica anidra para o tratamento da psorìase e uso de um agente siliconado
CL2004000884A1 (es) Composicion farmaceutica en forma de hidrogel que contiene un diester de acido carbonico, un alquilalcohol c2-c4, por lo menos una sustancia activa y una matriz de polimero; uso en el tratamiento de carencias esteroidales.
SE0403014D0 (sv) New protein formulation
UY29342A1 (es) Composicione antihelmintica
BR0108283A (pt) Uso de fosfato de estramustina ou um seu metabólito na preparação de um medicamento, agente para uso na potenciação da eficácia terapêutica de um taxano, combinação que potencia a eficácia terapêutica de um taxano, processo e método de potenciar a eficácia terapêutica de um taxano
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE (COMPLEMENTACAO).

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]